CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug ...

KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted ...

Aldevron, a global leader in the production of DNA, RNA and protein, has launched its latest innovation, Alchemytm cell-free DNA technology. This revolutionary technology represents a significant ...

Audiencerate, an innovative technology company, leader in the development of advanced solutions for digital marketing (MarTech) and online advertising (AdTech) announces that it has signed a ...

KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...

7. Sebetralstat for hereditary angioedema: By June 17, the U.S. market could have its first FDA-approved oral medication for the rare genetic health condition hereditary angioedema. The condition ...

Additionally, on January 6, 2025, the Committee granted one newly-hired employee inducement options to purchase an aggregate of 50,000 shares of KalVista common stock as an inducement material to such ...

Sebetralstat, our novel, investigational candidate for the oral, on-demand treatment of hereditary angioedema, is under regulatory review by the FDA with a PDUFA goal date of June 17, 2025.